A new partnership between PneumoDose and Noble Life Sciences has expanded client offerings to inhalation drug development and toxicology services. As a CRO, Noble Life Sciences will provide study design support and evaluation for drugs, pathogens, and different types of particulate matter.

Inhalation Delivery Explained

Inhalation delivery is a common method to administer prescription drugs to patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These local therapies reduce the dosage needed and mitigate systemic side effects common in drugs that must undergo first-pass metabolism. Currently, patients can be prescribed drugs to be delivered via pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers. In the recent years, this delivery platform has been gaining interest across the pharmaceutical and environmental industries for non-respiratory applications due to ease of use and versatility.

PneumoDose Technology

PneumoDose is the developer of an inhalation aerosol technology that has shown to directly deliver drug products to the lungs of various animal disease models. What makes it unique is that multiple animal subjects can be administered the experimental drug simultaneously, allowing for reduced drug amounts needed during testing and ensuring reproducibility over many experimental runs. It combines pharmaceutical microparticles and nanoclustering of biological reagents to optimize delivery and solubility into the alveoli sacs of rodents and other common research animal models. This results in a significant increase in localized concentration and bioavailability of the experimental treatment.

Changing Aerosol Drug Evaluation

One of the most expensive costs for development of new pharmaceuticals is preclinical in vivo studies. The most common method used to achieve this is intratracheal instillation, which includes varying the dosage among different animal types. This has several associated problems, including potential variability between doses, and nonhomogeneous pulmonary deposition. Due to costs of animal models, many researchers are left to use small animal models, which also makes using this method more challenging. The quality of the data produced from such a study design can vary, forcing pharmaceutical companies to repeat studies until there is a consistent trend present.

This technology gives no limit on the size of animal subjects that can be utilized during in vivo studies. Clients who utilize the in vivo services will no longer need to worry about affording large animal models or the challenges of working with small animal models. This has the added benefit of being able to produce comparable pulmonary disease states in models and test accordingly. The result is more consistent GLP or non-GLP datasets to support new drug development and decreased time-to-approval.

In vitro services are also supported by the PneumoDose technology. Cell cultures, dermal preparations, and ocular preparations can be exposed to different aerosols to determine toxicology levels in the early stages of development.

Noble Life Sciences’s in vivo capabilities, combined with PneumoDose’s technology, will help advance inhalation drug development. Contact us today for more information on inhalation drug delivery services.